Development of Antivirals against Respiratory Syncytial Virus

Perspectives in Medical Virology

Volumn 14, Issue , 2006, Pages 279-298

  Powell, Kenneth L ^a   Alber, Dagmar ^a  

^a Arrow Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750920325     PISSN: 01687069     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0168-7069(06)14009-4     Document Type: Review

References (73)

1. Andries K., Moeremans. Gevers M., Willebrords R., Sommen C., Lacrampe J., Janssens F., and Wyde P.R. Substituted benzimadazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res 60 (2003) 209-219
2. Antonis A.F.G., Schrijver R.S., Daus F., Steverink P.J.G.M., Stockhofe N., Hensen E.J., Langedijk J.P.M., and VanderMost R.G. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol 77 (2003) 12067-12073
3. Barnard D.L., Hill C.L., Gage T., Matheson J.E., Huffman J.H., Sidwell R.W., Otto M.I., and Schinazi R.F. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 34 (1997) 27-37
4. Barnard D.L., Huffman J.H., Meyerson L.R., and Sidwell R.W. Mode of inhibition of respiratory syncytial virus by a plant flavanoid, SP-303. Chemotherapy 39 (1993) 212-217
5. Bitko V., and Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its applications in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 1 (2001) 34
6. Bitko V., Musiyenko A., Shulyayeva O., and Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11 (2005) 50-55
7. Bond S, Sanford VA, Lambert JN, Lim CY, Mitchell JP, Draffan AG, Nearn RH. Polycyclic agents for the treatment of respiratory syncytial virus infections. 2005; WO 2005/061516 A1.
8. Budge P.J., Li Y., Beeler J.A., and Graham B.S. RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G. J Virol 78 (2004) 5015-5022
9. Calfee D.P., Peng A.W., Cass L.M., Lobo M., and Hayden F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 43 (1999) 1616-1620
10. Carter M.C., Alber D.A., Baxter R.C., Bithell S.K., Cockerill G.S., Dowdell V.C.L., Henderson E.A., Keegan S.J., Kelsey R.D., Stables J.N., Wilson L.J., and Powell K.L. Investigation of 1, 4-Benzodiazepine as inhibitors of respiratory syncytial virus. J Med Chem 49 (2006) 2311-2319
11. Chiba T., Shigeta S., and Numazaki Y. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol Pharm Bull 18 (1995) 1081-1083
12. Cianci C., Genovesi E.V., Lamb L., Medina I., Yang Z., Zadjura L., Yang H., D'Arienzo C., Sin N., Yu K.-L., Combrink K., Li Z., Colonno R., Meanwell N., Clark J., and Krystal M. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 48 (2004) 2448-2454
13. Cianci C., Langley D.R., Dischino D.D., Sun Y., Yu K.-L., Stanley A., Roach J., Li Z., Dalterio R., Colonno R., Meanwell N.A., and Krystal M. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad USA 101 (2004) 15046-15051
14. Cianci C., Meanwell N., and Krystall M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 55 (2005) 289-292
15. Cianci C., Yu K.-L., Combrink K., Sin N., Pearce B., Wang A., Civiello R., Voss S., Luo G., Kadow K., Genovesi E.V., Venables B., Gulgeze H., Trehan A., James J., Lamb L., Medina I., Roach J., Yang Z., Zadjura L., Colonno R., Clark J., Meanwell N., and Krystal M. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 48 (2004) 413-422
16. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Fields Virology (Knipe DM, Howley PM, editors). 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001; pp. 1433-1485.
17. Cook P.M., Eglin R.P., and Easton A.J. Pathogenesis of pneumovirus infections in mice: detection of pneumonia virus of mice and human respiratory syncytial virus mRNA in lungs of infected mice by in situ hybridization. J Gen Virol 79 (1998) 2411-2417
18. De Vicenzo J.P., El Saleeby C.M., and Bush A.J. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 191 (2005) 1861-1868
19. Dent J, Grieve S, Harland D, Alber D, Keegan S, Sanderson B, Lonsdale F, Thompson E, Smith G, Allan G, Powell K. Multi-dose safety and pharmacokinetics of A-60444, a novel compound active against respiratory syncytial virus (RSV). Abstract F438/287 45th ICAAC meeting, Washington, DC; 2005.
20. Douglas J.L., Panis M.L., Ho E., Lin K.-Y., Krawczyk S.H., Grant D.M., Cai R., Swaminathan S., Chen X., and Cihlar T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob Agents Chemother 49 (2005) 2460-2466
21. Dubovi E.J., Geratz J.D., and Tidwell R.R. Inhibition of respiratory syncytial virus by bis (5-amidino-2-benzimidazolyl) methane. Virology 103 (1980) 502-509
22. Eckstein F. Small non-coding RNAs as magic bullets. Trends Biochem Sci 30 (2005) 445-452
23. Falsey A.R., Formica M.A., Treanor J.J., and Walsh E.E. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 41 (2003) 4160-4165
24. Field H.J., Bell S.E., Elion G.B., Nash A.A., and Wildy P. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother 15 (1979) 554-561
25. Fytas G., Marakos P., Kolocouris N., Foscolos G.B., Pouli N., Vamvakides A., Ikeda S., and De Clercq E. 3-cyclopentyl-1-adamantanamines and adamantemethanamines. Antiviral activity evaluation and convulsion studies. Farmacology 49 (1994) 641-647
26. Gabrielsen B., Phelan M.J., Barthel-Rosa L., See C., Huggins J.W., Kefauver D.F., Monath T.P., Ussery M.A., Chmurny G.N., and Schubert E.M. Synthesis and antiviral evaluation of n-carboxamidine-substituted analogues of 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J Med Chem 35 (1992) 3231-3238
27. Gower T.L., and Graham B.S. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 45 (2001) 1231-1237
28. Groothius JR, Simoes E, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Price GA, Van Raden M, Hemming VG. for the Respiratory Syncytial Virus Immune Globulin Study Group Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. New Engl J Med 1993; 329: 1524-1530.
29. Hall C.B. Prevention of infections with respiratory syncytial virus: the hopes and hurdles ahead. Rev Inf Dis 2 (1980) 384-392
30. Hancock GE, Tebbey PW. Antiviral compositions which inhibit Paramyxovirus infection. WO 2005/066205 A2; 2005.
31. Hayden F.G., Andries K., and Janssen P.A. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 36 (1992) 727-732
32. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M, Pleconaril Respiratory Infection Study Group. (2003) Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Inf Dis 2003; 37: 1523-1532.
33. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersly N., Mills R.G., Ward P., and Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. J Am Med Assoc 282 (1999) 1246-1249
34. Herman R.C. Synthesis of respiratory syncytial virus RNA in cell-free extracts. J Gen Virol 70 (1989) 755-761
35. Hruska J.F., Bernstein J.M., Gordon Douglas Jr. R., and Hall C.B. Effects of Ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 17 (1980) 770-775
36. Huang R.C., Panin M., Romito R.R., and Huang Y.T. Inhibition of replication of human respiratory syncytial virus by 6-diazo-5-oxo-L-norleucine. Antiviral Res 25 (1994) 269-279
37. Huntley C.C., Weiss W.J., Gazumyan A., Buklan A., Feld B., Hu W., Jones T.R., Murphy T., Nikitenko A.A., O'Hara B., Prince G., Quartuccio S., Raifeld Y.E., Wyde P., and O'Connell J.F. RFI-641 a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 46 (2002) 841-847
38. Ikeda S., Neyts J., Verma S., Wickramasinghe A., Mohan P., and De Clercq E. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob Agents Chemother 38 (1994) 256-259
39. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiological study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 (1969) 405-421
40. Kimura K., Ishioka K., Hashimoto K., Mori S., Suzutani T., Bowlin T.L., and Shigeta S. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res 61 (2004) 165-171
41. Kimura K., Mori S., Tomita K., Ohno K., Takahashi K., Shigeta S., and Terada M. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res 47 (2000) 41-51
42. Lackey JW, Kinder DS, Tvermoes NA. Benzimidazole compounds and antiviral uses thereof. WO 02/092575 A1; 2002.
43. Larder B.A., Purifoy D.J.M., Powell K.L., and Darby G. Site-specific mutagenesis of AIDS virus reverse transcriptase. Nature 327 (1987) 716-717
44. Leaman D.W., Longano F.J., Okicki J.R., Soike K.F., Torrence P.F., Silverman R.H., and Cramer H. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292 (2002) 70-77
45. Lee F.E., Walsh E.E., Falsey A.R., Betts R.F., and Treanor J.J. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 63 (2004) 191-196
46. Maggon K., and Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 14 (2004) 149-168
47. Markland W., McQuaid T.J., Jain J., and Kwong A.D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 44 (2000) 859-866
48. Mason S.W., Lawetz C., Gaudette Y., Dô F., Scouten E., Legacé L., Simoneau B., and Liuzzi M. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32 (2004) 4758-4767
49. McKimm-Breschkin J. VP-14637 ViroPharma. Curr Opin Invest Drugs 1 (2000) 425-427
50. Nikitenko A.A., Raifeld Y.E., and Wang T.Z. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg Med Chem Lett 11 (2001) 1041-1044
51. Ohki S., Liu J.Z., Schaller J., and Welliver R.C. The compound DATEM inhibits respiratory syncytial virus fusion activity with epithelial cells. Antiviral Res 58 (2003) 115-124
52. Pastey M.K., Gower T.L., Spearman P.W., Crowe Jr. J.E., and Graham B.S. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat Med 6 (2000) 35-40
53. Perkins S.M., Webb D.L., Torrance S.A., El Saleeby C., Harrison L.M., Aitken J.A., Patel A., and DeVincenzo J.P. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 43 (2005) 2356-2362
54. Prince G.A., Horswood R.L., Berndt J., Suffin S.C., and Chanock R.M. Respiratory syncytial virus infection in inbred mice. Infect Immun 26 (1979) 764-766
55. Starpharma web site - www.starpharma.com
56. Sudo K., Konno K., Watanabe W., Shigeta S., and Yokata . Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbiol Immunol 45 (2001) 531-537
57. Sudo K., Miyazaki Y., Kojima N., Kobayashi M., Suzuki H., Shintani M., and Shimizu Y. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65 (2005) 125-131
58. Taylor G., Stott E.J., Hughes M., and Collins A.P. Respiratory syncytial virus infection in mice. Infect Immun 43 (1984) 649-655
59. Taylor G., Thomas L.H., Furze J.M., Cook R.S., Wyld S.G., Lerch R., Hardy R., and Wertz G.W. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J Gen Virol 78 (1997) 3195-3206
60. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
61. Tidwell R.R., Geratz J.D., Clyde Jr. W.A., Rosenthal K.U., and Dubovi E.J. Suppression of respiratory syncytial virus infection in cotton rats by Bis (5-Amidino-2-Benzimidazolyl) Methane. Antimicrob Agents Chemother 26 (1984) 591-593
62. Van den Hoogen B.G., Bestebroer T.M., Osterhaus A.D., and Fouchier R.A. Analysis of the genomic sequence of a human metapneumovirus. Virology 295 (2002) 119-132
63. Watanabe W., Sudo K., Sata R., Kajiyashiki T., Konno K., Shigeta S., and Yokota T. Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives. Biochem Biophys Res Commun 249 (1998) 922-926
64. Woolums A.R., Anderson M.L., Gunther R.A., Schelegle E.S., LaRochelle D.R., Singer R.S., Boyle G.A., Fribertshauser K.E., and Gershwin L.J. Am J Veter Res 60 (1999) 473-480
65. Wyde P.R., Ambrose M.W., Meyerson L.R., and Gibert B.E. Antiviral Res 20 2 (1993) 145-154
66. Wyde P.R., Ambrose M.W., Meyer H.L., and Gilbert B.E. Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14 (1990) 237-247
67. Wyde P.R., Ambrose M.W., Meyer H.L., Zolinski C.L., and Gilbert B.E. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res 14 (1990) 215-225
68. Wyde P.R., Chetty S.N., Timmerman P., Gilbert B.E., and Andries K. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antivir Res 60 (2003) 221-231
69. Wyde P.R., Laquerre S., Chetty S.N., Gilbert B.E., Nitz T.J., and Pevear D.C. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antivir Res 68 (2005) 18-26
70. Wyde P.R., Moore D.K., Pimentel D.M., and Blough H.A. Evaluation of the antiviral activity of n-(phosphonoacetyl)-l-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res 27 (1995) 59-69
71. Wyde P.R., Wilson S.Z., Petrella R., and Gilbert B.E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res 7 (1987) 211-220
72. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., and Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells and without obvious cytopathology. J Virol 76 (2002) 5654-5666
73. Zhang W., Yang H., Kong X., Mohapatra S., Juan-Vergara H.S., Hellermann G., Behera S., Singam R., Lockey R.F., and Mohapatra S.S. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 11 (2005) 56-62